. 2020 Apr 25;6(4):e03757. doi: 10.1016/j.heliyon.2020.e03757

Table 2.

Degree of improvement (based on KL grades 1, 2, 3) (n = 30 for placebo group, n = 37 for TCI633 group).

		Week 4		Week 8		Week 12		p value
		I4–I0 Difference (%) (SEM)	Improvement rate (%) (improved/total)	I8–I0 Difference (SE)	Improvement rate (%) (improved/total)	I12–I0 Difference (%) (SEM)	Improvement rate (%) (improved/total)	p value
sCTX-II	Placebo	-12.24 ± 3.08	47 (14/30)	-15.37 ± 3.65	43% (13/30)	-28.60 ± 5.26	53% (16/30)	0.002^a, 0.001^b, < 0.001^c
sCTX-II	TCI633	-18.40 ± 4.25	41 (15/37)	-23.63 ± 4.90	43% (16/37)	-41.58 ± 5.19	54% (20/37)	0.001^a, < 0.001^b, < 0.001^c
sCRP	Placebo	-33.11 ± 5.36	37 (11/30)	-40.74 ± 6.23	37% (11/30)	-43.34 ± 6.08	43% (13/30)	<0.001^a, < 0.001^b, < 0.001^c
sCRP	TCI633	-40.59 ± 4.79	62 (23/37)	-39.68 ± 5.98	65% (24/37)	-39.58 ± 5.34	57% (21/37)	<0.001^a, < 0.001^b, < 0.001^c

I4–I0 difference: the difference between week 0 and week 4. I8–I0 difference: the difference between week 0 and week 8. I12–I0 difference: the difference between week 0 and week 12. a: comparison between week 0 and week 4. b: comparison between week 0 and week 8. c: comparison between week 0 and week 12.